Nobilis Rhino CV

البلد: أيرلندا

اللغة: الإنجليزية

المصدر: HPRA (Health Products Regulatory Authority)

اشتر الآن

تأكيد الحساب خصائص المنتج (SPC)
12-06-2017

العنصر النشط:

Live attenuated avian rhinotracheitis virus strain trt 11/94

متاح من:

Intervet Ireland Limited

ATC رمز:

QI01AD01

INN (الاسم الدولي):

Live attenuated avian rhinotracheitis virus strain trt 11/94

جرعة:

.

الشكل الصيدلاني:

Lyophilisate for suspension for spray

نوع الوصفة الطبية :

POM: Prescription Only Medicine as defined in relevant national legislation

المجموعة العلاجية:

Chickens

المجال العلاجي:

avian rhinotracheitis virus

الخصائص العلاجية:

Immunological - Live Vaccine

الوضع إذن:

Authorised

تاريخ الترخيص:

2005-06-17

خصائص المنتج

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Nobilis Rhino CV.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE:
Per dose min. 10
1.5
TCID
50
*
and max. 10
3.7
TCID
50
of live attenuated avian rhinotracheitis virus strain 11/94.
For a list of excipients, see section 6.1.
*
Tissue Culture Infective Dose 50%
3 PHARMACEUTICAL FORM
Lyophilisate for suspension for oculonasal or spray application.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Chicken.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For broilers, future layers and breeders from one day of age.
_Broilers, future layers and breeders_
Active immunisation in order to reduce the frequency and the severity
of clinical signs due to infection with avian rhinotracheitis
virus (avian metapneumovirus). The onset of immunity is 3 weeks and
the duration of immunity is 16 weeks post-vaccination.
_Future layers and breeders_
Priming with Nobilis Rhino CV, followed by a second vaccination with
an inactivated vaccine containing the avian rhinotracheitis
virus strain But1#8544 before the onset of lay results in a reduction
of the clinical signs including egg drop, caused by infection
with avian rhinotracheitis virus. Protective immunity is maintained
for the normal laying period.
4.3 CONTRAINDICATIONS
None.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
I
R
I
S
H
M
E
D
I
C
I
N
E
S
B
O
A
R
D
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_3_
_0_
_/_
_0_
_3_
_/_
_2_
_0_
_1_
_2_
_C_
_R_
_N_
_ _
_7_
_0_
_1_
_2_
_2_
_3_
_0_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b
                                
                                اقرأ الوثيقة كاملة
                                
                            

تنبيهات البحث المتعلقة بهذا المنتج

عرض محفوظات المستندات